CARNA BIOSCIENCES

News Release

March 27, 2025
Carna Biosciences, Inc.

Carna announces an upcoming poster presentation at AACR Annual Meeting

Carna Biosciences, a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative therapies to treat serious unmet medical needs, announces that preclinical data for monzosertib (AS-0141) will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 in Chicago, Illinois.

Mozosertib is a potent, selective, and orally bioavailable small molecule inhibitor of CDC7 (cell division cycle 7) kinase, currently in a Phase 1 clinical study in Japan in patients with advanced, metastatic, relapsed or refractory malignancies. The poster will highlight new preclinical data on the synergistic effect of monzosertib in triplet combination with DNA methyltransferase (DNMT) inhibitor and B-cell/CLL lymphoma 2 (BCL2) inhibitor in acute myeloid leukemia (AML) models.

Presentation Details

Publication Number: 6867

Poster title:	Triplet combination of monzosertib, a potent CDC7 inhibitor, with DNMT and BCL2 inhibitors is highly active in human AML xenograft mouse models
Session:	Experimental and Molecular Therapeutics
Session date:	Wednesday 30 April, 2025
Presenter:	H. Furuichi, H. Endo, A. Arimura, Y. Nishioka, M. Sawa

The abstract is available at: https://www.abstractsonline.com/pp8/#!/20273/presentation/7524

About monzosertib (AS-0141)

CDC7 (cell division cycle 7) is a serine-threonine kinase that plays a critical role in DNA synthesis and is required for the activation of DNA replication origins throughout the S phase of the cell cycle. Inhibition of CDC7 in cancer causes lethal S phase or M phase progression, whereas normal cells survive, most likely through induction of cell cycle arrest at the DNA replication checkpoint. It has been reported in the literature that CDC7 is overexpressed in many types of cancers, therefore CDC7 is an attractive target for cancer drug development. Carna has successfully identified a selective and potent CDC7 inhibitor, monzosertib, with a unique mechanistic slow off-rate.

Contact:
Corporate Planning
Carna Biosciences, Inc.
TEL: +81-78-302-7075
https://www.carnabio.com/english/